Article
A phase 1 study of veliparib, a PARP-1/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer.
EBioMedicine - 1 Feb 2019
Tuli Richard, Shiao Stephen L, Nissen Nicholas, Tighiouart Mourad, Kim Sungjin, Osipov Arsen, Bryant Miranda, Ristow Lindsey, Placencio-Hickok Veronica, Hoffman David, Rokhsar Sepehr, Scher Kevin, Klempner Samuel J, Noe Paul, Davis M J, Wachsman Ashley, Lo Simon, Jamil Laith, Sandler Howard, Piantadosi Steven, Hendifar Andrew
Abstract excerpt
BACKGROUND: Locally advanced pancreatic cancer (LAPC) has a dismal prognosis with current treatment modalities and one-third of patients die from local progression of disease. Preclinical studies with orthotopic PC demonstrated dramatic synergy between radiotherapy (RT) and the poly(ADP-ribose) polymerase-1/2 inhibitor (PARPi), veliparib. We conducted a phase I trial of gemcitabine, radiotherapy and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.